A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
Conditions
Palmoplantar Pustulosis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
LEO Pharma Investigational Site, Fountain Valley, California, United States
LEO Pharma Investigational Site, Douglasville, Georgia, United States
LEO Pharma Investigational Site, West Bloomfield, Michigan, United States
LEO Pharma Investigational Site, Elmhurst, New York, United States
LEO Pharma Investigation Site, Mayfield Heights, Ohio, United States
LEO Pharma Investigational Site, Portland, Oregon, United States
LEO Pharma Investigational Site, Philadelphia, Pennsylvania, United States
LEO Pharma Investigational Site, Calgary, Alberta, Canada
LEO Pharma Investigational Site, Surrey, British Columbia, Canada
LEO Pharma Investigational Site, Winnipeg, Manitoba, Canada
LEO Pharma Investigational Site, Fredericton, New Brunswick, Canada
LEO Pharma Investigational Site, Hamilton, Ontario, Canada
LEO Pharma Investigational Site, Hamilton, Ontario, Canada
LEO Pharma Investigational Site, Markham, Ontario, Canada
LEO Pharma Investigational Site, Waterloo, Ontario, Canada
LEO Pharma Investigational Site, Montreal, Quebec, Canada
LEO Pharma Investigational Site, Bad Bentheim, Germany
LEO Pharma Investigational Site, Dresden, Germany
LEO Pharma Investigational Site, Göttingen, Germany
LEO Pharma Investigational Site, Kiel, Germany
LEO Pharma Investigational Site, Lübeck, Germany
LEO Pharma Investigational Site, Manheim, Germany
LEO Pharma Investigational Site, Münster, Germany
LEO Pharma Investigational Site, Osnabrück, Germany
LEO Pharma Investigational Site, Witten, Germany
LEO Pharma Investigational Site, Bialystok, Poland
LEO Pharma Investigational Site, Iwonicz-Zdrój, Poland
LEO Pharma Investigational Site, Lodz, Poland
LEO Pharma Investigational Site, Lublin, Poland
LEO Pharma Investigational Site, Rzeszów, Poland
LEO Pharma Investigational Site, Warsaw, Poland
LEO Pharma Investigational Site, Wroclaw, Poland
LEO Pharma Investigational Site, Wroclaw, Poland
LEO Pharma Investigational Site, Bristol, United Kingdom
LEO Pharma Investigational Site, London, United Kingdom
LEO Pharma Investigational Site, Newcastle upon Tyne, United Kingdom
LEO Pharma Investigational Site, Salford, United Kingdom
LEO Pharma Investigational Site, Stourbridge, United Kingdom
Study leads
Medical Expert
Study Director
LEO Pharma